
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen has demonstrated significant sales growth, with a remarkable 40% increase in total sales in the third quarter of 2025 compared to the same period in 2024, and notable performance from key products such as Repatha and Tezspire. The company's strategic investments in R&D, projected to grow over 20% in 2025 compared to 2024, highlight its commitment to innovation and bolstering its product pipeline. Additionally, the upward revision of FY25 revenue guidance to a range of $35.8-$36.6 billion further underscores Amgen's robust performance across its established franchises and signals continued momentum in the biotechnology sector.
Bears say
The financial outlook for Amgen appears negative, primarily due to projected revenue growth of only approximately 1% in 2026, which is further complicated by anticipated worldwide sales declines of about 28% and 39% for two of its flagship products, Prolia and Xgeva, respectively. Additionally, the company's research and development expenditures are expected to increase at a slower pace compared to prior years, indicating potential challenges in sustaining innovation and growth. While Amgen's emerging products and pipeline therapies show promise, there remains considerable uncertainty regarding their effectiveness in compensating for the anticipated decline in revenue following the loss of exclusivity for major product franchises.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares